Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A Clinical Trial

Official title:

A Phase 1/2 Open-label Safety and Dose-finding Study of BAY2599023 (DTX201), an Adeno-associated Virus (AAV) hu37-mediated Gene Transfer of B-domain Deleted Human Factor VIII, in Adults With Severe Hemophilia A

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03588299
• Other study ID #: 19429
• Secondary ID: 2023-505827-29-0
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: November 7, 2018
• Est. completion date: November 30, 2026

Study information

• Verified date: June 2024
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a healthy copy the human body may produce clotting factor on its own. Hemophilia A is a bleeding disorder in which the human body does not have enough clotting factor VIII, a protein that controls bleeding. Researcher want to find the optimal dose of BAY 2599023 (DTX201) so that the body may produce enough clotting factor on its own.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 11
• Est. completion date: November 30, 2026
• Est. primary completion date: November 3, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males age 18 years or older.

• Confirmed diagnosis of hemophilia A as evidenced by their medical history with plasma FVIII activity levels < 1% of normal or at screening.

• Have >150 exposure days (EDs) to FVIII concentrates (recombinant or plasma-derived).

If on prophylaxis, are required to be willing to stop prophylactic treatment at specified time points throughout the study or If on-demand: should have had > 4 bleeding events in the last 52 weeks

• Agree to use reliable barrier contraception.

Exclusion Criteria:

• History of allergic reaction to any FVIII product.

• Clinically relevant findings in the physical examination considered critical by the treating physician, including obesity with BMI > 35 kg/m*2

• Current evidence of measurable inhibitor against factor VIII, prior history of inhibitors to FVIII protein or clinical history suggestive of inhibitor.

• Evidence of active hepatitis B or C.

• Currently on antiviral therapy for hepatitis B or C.

• Significant underlying liver disease.

• Serological evidence of HIV-1 or HIV-2 with CD4 counts =200/mm*3; HIV+ and stable participants with CD4 count >200/mm*3 and undetectable viral load are eligible to enroll.

• Detectable antibodies reactive with AAVhu37capsid.

• Participant with another bleeding disorder that is different from hemophilia A (e.g., von Willebrand disease, hemophilia B).

• Participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an investigational product within the last 12 weeks.

• Known or suspected hypersensitivity or allergic reaction to trial product(s) or related FVIII products or any component of BAY2599023 (DTX201), or a contraindication to prednisolone

Related Conditions & MeSH terms

• Hemophilia A

Intervention

Drug:
• BAY2599023 (DTX201)
Single escalating doses with 4 dose steps; Single intravenous (IV) administration.

Locations

Country	Name	City	State
Bulgaria	SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD	Sofia
France	Hopital Necker les enfants malades - Paris	Paris
France	Hôpital Pontchaillou	Rennes Cedex
Germany	Vivantes Klinikum im Friedrichshain	Berlin
Germany	Universitätsklinikum des Saarlandes	Homburg	Saarland
Netherlands	Academisch Medisch Centrum (AMC)	Amsterdam
Netherlands	Universitair Medisch Centrum Groningen	Groningen
Netherlands	Erasmus Medisch Centrum	Rotterdam
Netherlands	University Medical Center Utrecht	Utrecht
United Kingdom	Manchester Royal Infirmary	Manchester
United States	C.S. Mott Children's Hospital	Ann Arbor	Michigan
United States	Arkansas Children's Hospital	Little Rock	Arkansas
United States	University of Wisconsin - Madison	Madison	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
Bayer	Ultragenix pharmaceutical

Countries where clinical trial is conducted

United States,  Bulgaria,  France,  Germany,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with adverse events (AEs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and AEs/SAEs of special interest		Up to 5 years
Secondary	Expression pattern of FVIII activity.	Determined using both a one-stage assay and chromogenic assay.	Up to 5 years
Secondary	Proportion of patients in the respective dose step, that reached an expression of FVIII above 5%		At 6 months and 12 months following the IV administration of BAY2599023

External Links

•   Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.